What Is Fatty Liver Disease (Hepatic Steatosis) And How To Treat It?
Clinician's Perspective:
• The condition formerly known as Non-Alcoholic Fatty Liver Disease (NAFLD) has been officially renamed Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) to better reflect its origins in metabolic health.
• MASLD in the general population has risen from 25% in 2016 to more than 30% today, representing a massive shift in public health requirements.
• A two-step screening process for at-risk groups, beginning with the blood test to calculate the FIB-4 index (a blood-based score) followed by Transient Elastography (brand Fibroscan, an ultrasound-based technology to measure liver stiffness).
• Weight Loss as the Primary Cure: To achieve the regression of Fibrosis (the scarring of liver tissue), a sustained total body weight loss of at least 10% is necessary.
• New Medicine: For the first time, a specific medication—Resmetirom—is recommended for adults with significant liver scarring (Stage 2 or higher), marking a disruption in the treatment landscape.
• Surgical and Incretin Interventions: Bariatric Surgery (weight-loss surgery) and GLP-1RAs (incretin-based therapies) is recommended for managing the underlying obesity and Type 2 Diabetes that drive liver damage.
MASLD: A New Paradigm in Metabolic & Liver Health
The transition from Non-Alcoholic Fatty Liver Disease (NAFLD) to Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) represents a fundamental shift in clinical strategy. Rather than defining the disease by what it isn't (alcohol-related), the new nomenclature focuses on the metabolic drivers that cause it.
The Global and Local Context
Rising Prevalence: Global MASLD rates have surged from 25% in 2016 to over 30% today, signaling a public health crisis. In Singapore, hepatic steatosis is frequently an incidental finding during ultrasound scans. Given the higher metabolic risk at lower BMIs in Asian populations, early identification is critical.
Diagnostic Criteria for MASLD
To be diagnosed with MASLD, a patient must present with hepatic steatosis (fatty liver) in conjunction with at least one of the following cardiometabolic risk factors:
Increased Adiposity: Elevated BMI or waist circumference.
Hyperglycemia: Elevated fasting blood sugar levels or a diagnosis of Type 2 Diabetes.
Hypertension: High blood pressure or use of antihypertensive medication.
Dyslipidemia: Elevated triglycerides or low HDL cholesterol levels.
Identifying the At-Risk Population
The data reveals that MASLD is not a silent, isolated condition but is instead tightly linked to the "metabolic syndrome." While general population screening is not yet advised, the guidelines recommend proactive case-finding in specific groups. This includes individuals with Type 2 Diabetes or those with abdominal obesity (waist circumference ≥94 cm for men and ≥80 cm for women in European cohorts; notably, these thresholds are lower for Asian populations in Singapore, often starting at 90 cm for men and 80 cm for women).
The Diagnostic Pathway: FIB-4 and Elastography
To avoid unnecessary and invasive liver biopsies, the guidelines advocate for a "stepwise" non-invasive approach.
- FIB-4 Index: A simple calculation using age, liver enzymes, and platelet counts.
- Transient Elastography: If the FIB-4 score is elevated, clinicians use this specialized ultrasound to measure the "stiffness" of the liver.
The stage of Fibrosis (liver scarring) is the single most important predictor of liver-related outcomes, including the risk of Hepatocellular Carcinoma (the most common type of primary liver cancer).
Treatment: The Power of 10%
Lifestyle modification remains the cornerstone of treatment. While a 5% weight loss can reduce liver fat, the data identifies that a 7-10% weight loss is required to resolve Metabolic Associated Steato-Hepatitis (MASH; liver inflammation and cell damage). Resolution of inflammation is the key to prevention of Liver Fibrosis (liver scarring). Crucially, to reverse existing Fibrosis, a weight loss of 10% or more is typically required.
The Role of Pharmacotherapy
A significant breakthrough in these guidelines is the inclusion of Resmetirom. In clinical trials, this liver-directed thyroid hormone receptor agonist demonstrated the ability to improve liver scarring and resolve inflammation in adults with significant fibrosis.
Furthermore, GLP-1RAs (medications like semaglutide or tirzepatide) are strongly recommended for their primary indications—managing Type 2 Diabetes and Obesity—due to their profound effect on metabolic health and indirect benefits to the liver.
Bariatric Surgery
For individuals with a Body Mass Index (BMI) over 35 kg/m² (or 32.5 kg/m² in Asian populations with comorbidities), Bariatric Surgery (metabolic surgery) is presented as a highly effective option. The data shows that this surgery can lead to the resolution of Metabolic Associated Steato Hepatitis (MASH) in up to 84% of cases.
As the global prevalence of MASLD continues to climb above 30%, these guidelines provide a sound strategy to transition from reactive treatment to proactive metabolic management.
Evidence Strength: This comprehensive guideline is based on high-level evidence including randomized controlled trials and systematic reviews, following a rigorous multi-society Delphi consensus process. Final Rating: ★★★★★
Source: Read the full study
